MAG
ABBV icon

Meadowbrook Advisors Group’s AbbVie ABBV Stock Holding History

Meadowbrook Advisors Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
8,522
-486
-5% -$105K 1.15% 22
2026
Q1 		$1.96M Buy
9,008
+8
+0.1% +$1.77K 1.16% 28
2025
Q4 		$2.06M Buy
+9,000
New +$2.05M 1.15% 29

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Meadowbrook Advisors Group's ABBV Position: Q2 2026 in Review

Meadowbrook Advisors Group reduced its AbbVie (ABBV) stake by 5.4% in Q2 2026, selling an estimated $105K and leaving 8,522 shares worth $2.14M. The position accounts for 1.15% of the portfolio, ranked #22.

Meadowbrook Advisors Group first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Meadowbrook Advisors Group held 8,522 shares of AbbVie worth $2.14M as of Q2 2026.
  • Meadowbrook Advisors Group sold 486 AbbVie shares in Q2 2026, an estimated $105K.
  • AbbVie made up 1.15% of Meadowbrook Advisors Group's portfolio in Q2 2026, its #22 holding.
  • Meadowbrook Advisors Group first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Meadowbrook Advisors Group's 13F filing for Q2 2026, filed 7 Aug 2026.